# Safety and Efficacy of Liraglutide in Combination With an OAD in Subjects With Type 2 Diabetes Insufficiently Controlled on OAD Alone

> **NCT01512108** · PHASE3 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 363 (actual)

## Conditions studied

- Diabetes
- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** liraglutide
- **DRUG:** oral anti-diabetic drug

## Key facts

- **NCT ID:** NCT01512108
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-01-10
- **Primary completion:** 2013-04-26
- **Final completion:** 2013-04-26
- **Target enrollment:** 363 (ACTUAL)
- **Last updated:** 2017-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01512108

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01512108, "Safety and Efficacy of Liraglutide in Combination With an OAD in Subjects With Type 2 Diabetes Insufficiently Controlled on OAD Alone". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01512108. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*